ste11ar
Lv1
20 积分
2022-03-16 加入
-
Sintilimab plus chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer with disease progression after EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): second interim analysis from a double-blind, randomised, placebo-controlled, phase 3 trial
6天前
已完结
-
Sintilimab plus bevacizumab biosimilar IBI305 and chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer who progressed on EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): first interim results from a randomised, double-blind, multicentre, phase 3 trial
6天前
已完结
-
Sunvozertinib for patients in China with platinum-pretreated locally advanced or metastatic non-small-cell lung cancer and EGFR exon 20 insertion mutation (WU-KONG6): single-arm, open-label, multicentre, phase 2 trial
6天前
已完结
-
Repotrectinib effective in ROS1-fusion-positive NSCLC
12天前
已完结
-
Pathways and targeting avenues of BRAF in non-small cell lung cancer
13天前
已完结
-
BRAF/MEK inhibition in NSCLC: mechanisms of resistance and how to overcome it
13天前
已完结
-
Diverse alterations associated with resistance to KRAS(G12C) inhibition
14天前
已完结
-
Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRASG12C mutation: a randomised, open-label, phase 3 trial
15天前
已完结
-
Restoring hippocampal glucose metabolism rescues cognition across Alzheimer’s disease pathologies
17天前
已完结
-
Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial
18天前
已完结